New medicines with chemotherapy after short radiation for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two new immune-related medicines (an anti–PD-1 drug and an adenosine blocker) added to standard chemotherapy after a short course of radiation for rectal cancer. It aims to improve cancer control while checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer confirmed as adenocarcinoma
- You are 18 or older and can do normal activities most of the time (ECOG 0–1)
- Your tumor can be fully removed with surgery after treatment, and it’s not in distant organs (no metastases)
- You have not had radiation or chemotherapy for rectal cancer before
- You don’t have certain lung, immune, or ongoing infection problems that could make treatment unsafe
- Your blood counts and liver function are high enough for chemotherapy (for example hemoglobin > 8 and platelets > 150)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.